Violacein anticancer activity is enhanced under hypoxia

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1731-1736

  Hashimi, Saeed M ^a   Xu, Tiefeng ^b   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Hypoxia; Oncolytic Salmonella; Violacein

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; UNCLASSIFIED DRUG; VIOLACEIN; INDOLE DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIZATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HCT116 CELL LINE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; BACTERIUM TRANSFORMATION; BAGG ALBINO MOUSE; BREAST TUMOR; CARCINOMA; CELL HYPOXIA; CHROMOBACTERIUM; COLON TUMOR; DRUG EFFECTS; DRUG SCREENING; ESCHERICHIA COLI; GENETICS; HEAD AND NECK TUMOR; LUNG TUMOR; MELANOMA; MULTIGENE FAMILY; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CHROMOBACTERIUM; COLONIC NEOPLASMS; ESCHERICHIA COLI; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIGENE FAMILY; NEOPLASMS, EXPERIMENTAL; SALMONELLA TYPHIMURIUM; TRANSFORMATION, BACTERIAL; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924872873     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3781     Document Type: Article

References (29)

1. Tabata K, Yamazaki Y, Okada M, et al: Diarylheptanoids derived from Alpinia officinarum induce apoptosis, S-phase arrest and differentiation in human neuroblastoma cells. Anticancer Res 29: 4981-4988, 2009.
2. Uddin S, Khan AS and Al-Kuraya KS: Developing curcumin into a viable therapeutic for lymphoma. Expert Opin Investig Drugs 18: 57-67, 2009.
3. Wang TT, Schoene NW, Kim YS, Mizuno CS and Rimando AM: Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 54: 335-344, 2010.
4. Li C, Hashimi SM, Cao S, et al: The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells. Evid Based Complement Alternat Med 2013: 849054, 2013.
5. August PR, Grossman TH, Minor C, et al: Sequence analysis and functional characterization of the violacein biosynthetic pathway from Chromobacterium violaceum. J Mol Microbiol Biotechnol 2: 513-519, 2000.
6. Pemberton JM, Vincent KM and Penfold RJ: Cloning and heterologous expression of the violacein biosynthesis gene cluster from Chromobacterium violaceum. Curr Microbiol 22: 355-358, 1991.
7. Andrighetti-Fröhner CR, Antonio RV, Creczynski-Pasa TB, Barardi CR and Simões CM: Cytotoxicity and potential antiviral evaluation of violacein produced by Chromobacterium violaceum. Mem Inst Oswaldo Cruz 98: 843-848, 2003.
8. Antonisamy P and Ignacimuthu S: Immunomodulatory, analgesic and antipyretic effects of violacein isolated from Chromobacterium violaceum. Phytomedicine 17: 300-304, 2010.
9. Antonisamy P, Kannan P and Ignacimuthu S: Anti-diarrhoeal and ulcer-protective effects of violacein isolated from Chromobacterium violaceum in Wistar rats. Fundam Clin Pharmacol 23: 483-490, 2009.
10. Cazoto LL, Martins D, Ribeiro MG, Durán N and Nakazato G: Antibacterial activity of violacein against Staphylococcus aureus isolated from bovine mastitis. J Antibiot 64: 395-397, 2011.
11. Leon LL, Miranda CC, De Souza AO and Durán N: Antileishmanial activity of the violacein extracted from Chromobacterium violaceum. J Antimicrob Chemother 48: 449-450, 2001.
12. Lichstein HC and Van De Sand VF: The antibiotic activity of violacein, prodigiosin, and phthiocol. J Bacteriol 52: 145-146, 1946.
13. Bromberg N, Dreyfuss JL, Regatieri CV, et al: Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem Biol Interact 186: 43-52, 2010.
14. de Carvalho DD , Costa FT, Durán N and Haun M: Cytotoxic activity of violacein in human colon cancer cells. Toxicol In Vitro 20: 1514-1521, 2006.
15. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Durán N and Peppelenbosch MP: Molecular mechanism of violacein-mediated human leukemia cell death. Blood 104: 1459-1464, 2004.
16. Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV and Hardwick JC: Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 27: 508-516, 2006.
17. Martins D, Frungillo L, Anazzetti MC, Melo PS and Durán N: Antitumoral activity of L-ascorbic acid-poly-D,L-(lactide-coglycolide) nanoparticles containing violacein. Int J Nanomed 5: 77-85, 2010.
18. Melo PS, Justo GZ, de Azevedo MB, Durán N and Haun M: Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology 186: 217-225, 2003.
19. Melo PS, Maria SS, Vidal BC, Haun M and Durán N: Violacein cytotoxicity and induction of apoptosis in V79 cells. In Vitro Cell Dev Biol Anim 36: 539-543, 2000.
20. Queiroz KC, Milani R, Ruela-De-Sousa RR, et al: Violacein induces death of resistant leukaemia cells via kinome reprogramming, endoplasmic reticulum stress and Golgi apparatus collapse. PLoS One 7: e45362, 2012.
21. Saraiva VS, Marshall JC, Cools-Lartigue J and Burnier MN Jr.: Cytotoxic effects of violacein in human uveal melanoma cell lines. Melanoma Res 14: 421-424, 2004.
22. Ahmetagic A and Pemberton JM: Stable high level expression of the violacein indolocarbazole anti-tumour gene cluster and the Streptomyces lividans amyA gene in E. coli K12. Plasmid 63: 79-85, 2010.
23. Durán N, Justo GZ, Ferreira CV, Melo PS, Cordi L and Martins D : Violacein: properties and biological activities. Biotechnol Appl Biochem 48: 127-133, 2007.
24. Rosenberg SA, Spiess PJ and Kleiner DE: Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 25: 218-225, 2002.
25. Durán N, Antonio RV, Haun M and Pilli RA: Biosynthesis of a trypanocide by Chromobacterium violaceum. World J Microbiol Biotechnol 10: 686-690, 1994.
26. Rohwer N and Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201, 2011.
27. Tirino V, Desiderio V, Paino F, et al: Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27: 13-24, 2013.
28. Hashimi SM, Yu S, Alqurashi N, Ipe DS and Wei MQ: Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells. Int J Oncol 42: 1911-1918, 2013.
29. Cunningham C and Nemunaitis J: A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 12: 1594-1596, 2001.